CAR T cells more powerful when built with CRISPR, researchers find

February 22, 2017, Memorial Sloan Kettering Cancer Center

Researchers from Memorial Sloan Kettering Cancer Center (MSK) have harnessed the power of CRISPR/Cas9 to create more-potent chimeric antigen receptor (CAR) T cells that enhance tumor rejection in mice. The unexpected findings, published in Nature on February 22, uncover facets of CAR immunobiology and underscore the potential of CRISPR/Cas9 genome editing to advance immunotherapies for cancer.

CRISPR is a genome-editing tool that enables scientists to cut and manipulate a cell's DNA with high precision. In the Nature paper, MSK investigators show that CRISPR technology can deliver the CAR gene to a very specific location in the genome of the T cell. This precise approach creates CAR T with more stamina—they can kill for longer because they are less prone to becoming exhausted. This could eventually lead to safer, more effective use of this powerful form of immunotherapy in patients.

"Cancer cells are relentless in their attempt to evade treatment, so we need CAR T cells that can match and outlast them," explained Michel Sadelain, MD, PhD, senior author on the Nature paper and Director of the Center for Cell Engineering and the Gene Transfer and Gene Expression Laboratory at MSK. "This new discovery shows that we may be able to harness the power of genome editing to give these 'living therapies' a built-in boost. We are eager to continue exploring how genome-editing technology could give us the next generation of CAR T cell therapy."

Some of the first clinical trials using CRISPR technology are currently in the planning stages. Dr. Sadelain and his team aim to eventually explore the safety and efficacy of these CRISPR-built CAR T cells in a trial. Currently, CAR T cells are usually made using a retroviral or lentiviral technology to deliver the CAR gene into the T cells. This delivery method results in the CAR gene being inserted at random into the genome of the recipient cells, which can result in unwanted genetic side effects.

Explore further: Tuberculosis-resistant cows developed for the first time using CRISPR technology

More information: Justin Eyquem et al, Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection, Nature (2017). DOI: 10.1038/nature21405

Related Stories

Tuberculosis-resistant cows developed for the first time using CRISPR technology

January 31, 2017
CRISPR/Cas9 gene-editing technology has been used for the first time to successfully produce live cows with increased resistance to bovine tuberculosis, reports new research published in the open access journal Genome Biology.

Watching gene editing at work to develop precision therapies

January 24, 2017
University of Wisconsin-Madison engineers have developed methods to observe gene editing in action, and they're putting those capabilities to work to improve genetic engineering techniques.

Genome surgery with CRISPR-Cas9 to prevent blindness

February 16, 2017
It is estimated that almost one in every ten people over 65 has some signs of age-related macular degeneration (AMD), and its prevalence is likely to increase as a consequence of the aging population. AMD is a form of blindness, ...

Recommended for you

Fetal gene therapy prevents fatal neurodegenerative disease

July 16, 2018
A fatal neurodegenerative condition known as Gaucher disease can be prevented in mice following fetal gene therapy, finds a new study led by UCL, the KK Women's and Children's Hospital and National University Health System ...

New study finds that fat consumption is the only cause of weight gain

July 13, 2018
Scientists from the University of Aberdeen and the Chinese Academy of Sciences have undertaken the largest study of its kind looking at what components of diet—fat, carbohydrates or protein—caused mice to gain weight.

Basic research in fruit flies leads to potential drug for diseases afflicting millions

July 13, 2018
River blindness and elephantiasis are debilitating diseases caused by parasitic worms that infect as many as 150 million people worldwide. They are among the "neglected tropical diseases" for which better treatments are desperately ...

Light based cochlear implant restores hearing in gerbils

July 12, 2018
A team of researchers with members from a variety of institutions across Germany has developed a new type of cochlear implant—one based on light. In their paper published in the journal Science Translational Medicine, the ...

Researchers discover gene that controls bone-to-fat ratio in bone marrow

July 12, 2018
In an unexpected discovery, UCLA researchers have found that a gene previously known to control human metabolism also controls the equilibrium of bone and fat in bone marrow as well as how an adult stem cell expresses its ...

Intensive care patients' muscles unable to use fats for energy

July 12, 2018
The muscles of people in intensive care are less able to use fats for energy, contributing to extensive loss of muscle mass, finds a new study co-led by UCL, King's College London and Guy's and St Thomas' NHS Foundation Trust.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.